Skip to Primary Navigation

Skip to main content

McKinsey OxyContin settlement illustrates need for robust comms surveillance and archiving

The matter-of-fact narrative is scathing of the moral and ethical void at Purdue as well as the behavior at the consulting firm.

Thomas Hyrkiel, Julie DiMauro

Purdue Pharma HQ in downtown Stamford, Connecticut. Purdue Pharma was the maker of OxyContin and a profitable McKinsey client. Photo by Drew Angerer/Getty Images
Click to share on Facebook (Opens in new window/tab) Click to share on X (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

In December we briefly reported on a significant DOJ fine of $650m against McKinsey & Company. This fine was levied as part of a criminal and civil settlement between the consulting firm and the DOJ in relation to the firm’s work with Purdue Pharma on the marketing and sale of

, , , , , , ,

Get full access, free for a month

Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial
Sign in

What’s included:

  • Every new article, plus our 6,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience